Tetralogic Pharmaceuticals Corporation (TLOG)

Overview

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company concentrating on the discovery and development of small molecule therapeutics aimed at oncology and infectious diseases fields. Initially known as Gentara Corporation, the company underwent a name change to TetraLogic Pharmaceuticals Corporation in January 2006. Established in 2001, it leverages its expertise in apoptosis and other cell-death pathways to address unmet medical needs in cancer and infectious diseases. Headquartered in Malvern, Pennsylvania, TetraLogic collaborates with esteemed institutions like the Walter and Eliza Hall Institute of Medical Research, exploring the potential of SMAC-mimetics, including birinapant, in treating infectious diseases.

Products and Services

• Birinapant

This is a clinical-stage small molecule designed to act as a Second Mitochondrial Activator of Caspases-mimetic. It mimics the body's natural processes to induce cell death in damaged cells, a critical mechanism for combating cancer cells. By targeting the apoptotic pathway directly, birinapant has the potential to treat various cancers effectively.

• SHAPE

TetraLogic's proprietary histone deacetylase inhibitor, SHAPE, is formulated for topical application and is under development for the treatment of early-stage cutaneous T-cell lymphoma. By inhibiting the histone deacetylase enzyme, SHAPE aims to modulate gene expression in a way that suppresses tumor growth and progression, offering a novel approach to lymphoma treatment.